MRNA Therapeutics Contract Development And Manufacturing Organization Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 10.30 Billion |
| Market Size (2029) | USD 18.60 Billion |
| CAGR (2024 - 2029) | 12.49 % |
| Fastest Growing Market | North America |
| Largest Market | Asia Pacific |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
MRNA Therapeutics Contract Development And Manufacturing Organization Market Analysis
The MRNA Therapeutics Contract Development And Manufacturing Organization Market size is estimated at USD 10.30 billion in 2024, and is expected to reach USD 18.60 billion by 2028, growing at a CAGR of 12.49% during the forecast period (2024-2028).
Key drivers of market growth include increased research and funding for mRNA therapeutics and the rising adoption of mRNA vaccines. The intensified focus on mRNA-based treatments, spanning vaccines, cancer therapies, and rare diseases, is amplifying the demand for CDMOs specializing in mRNA production and development.
Collaborations among pharmaceutical companies, biotech firms, research institutions, and CDMOs have accelerated the development and production of mRNA-based therapies. For instance, in January 2022, Merck finalized a deal to acquire Exelead, a biopharmaceutical CDMO, for approximately USD 780 million in cash. This acquisition aims to bolster Merck’s CDMO offerings for mRNA therapeutics. Similarly, in October 2023, AGC Biologics expanded its facility in Heidelberg, Germany, introducing a new mRNA production line. This advanced line, equipped with cutting-edge single-use technology, offers the flexibility to handle multiple projects concurrently, ensuring quicker timelines and faster turnover. This enhancement positions the CDMO to cater to a broader range of developers in need of mRNA materials. Such strategic moves are anticipated to propel the market during the forecast period.
Moreover, a surge in research activities for mRNA vaccines and therapeutics, coupled with a robust pipeline, is set to fuel market growth. As of March 2024, clinicaltrials.gov recorded 424 clinical studies tied to mRNA therapeutics. This increase in studies underscores a burgeoning demand for mRNA production capacities. Additionally, the intricate and costly nature of producing mRNA therapeutics and vaccines necessitates specialized expertise. Consequently, mRNA developers are increasingly turning to CDMOs for outsourcing, further propelling the market growth.
In summary, bolstered by rising collaborations, increased research funding, and a robust pipeline, the mRNA therapeutics CDMO market is poised for growth. However, potential regulatory hurdles and compliance challenges in outsourcing are anticipated to hamper the market growth.
MRNA Therapeutics Contract Development And Manufacturing Organization Market Trends
Infectious Diseases Segment is Expected to Hold a Significant Share Over the Forecast Period
The rising burden of infectious diseases is one of the key factors for the increasing demand for mRNA-based therapeutics and, thus, for CDMO. For instance, as per the data from the Joint United Nations Program on HIV/AIDS (UNAIDS) published in May 2023, there were around 38.4 million people across the world suffering from HIV. The high burden of HIV is expected to fuel the demand for advanced therapeutics, which, in turn, is likely to contribute to the segment’s growth in the coming years.
Moreover, an increasing strategic partnership and investments in mRNA vaccines and therapeutics research are also expected to contribute to the segment growth. For instance, in February 2023, GenScript ProBio, a CDMO, and RVAC Medicines Pte Ltd, a biotechnology company focusing on the development and commercialization of mRNA therapeutics and vaccines, announced an agreement to establish a strategic partnership for the manufacturing of GMP-grade plasmid DNA (pDNA) for its mRNA COVID-19 vaccine candidate, RVM-V001, along with collaboration for future therapeutic pipelines.
Hence, the increasing burden of infectious diseases, increasing funding for mRNA therapeutics, and strategic activities by the market players are expected to boost the segment growth over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America's mRNA CDMO market is set to expand, driven by established research facilities, substantial research and development (R&D) investments in mRNA therapeutics, and the increasing prevalence of chronic diseases. Additionally, the strong presence of key market players and their strategic initiatives further support this growth.
With rising investments and collaborations, the demand for CDMO services is expected to increase, propelling market expansion. For instance, in July 2023, Vernal Biosciences, a CDMO, secured USD 20 million in funding, led by Ampersand Capital Partners and Charles River Labs, with contributions from Dynamk Capital and the Vermont Center for Emerging Technologies. This funding aims to enhance mRNA and lipid nanoparticle (LNP) manufacturing capabilities. Such financial support enables CDMO players to diversify their service portfolios, driving market growth.
Furthermore, strategic initiatives by market players, including service expansions, collaborations, and partnerships, are anticipated to contribute to market growth. For instance, in May 2023, Moderna Inc. entered into a long-term agreement with Ontario-based Novocol Pharma, a sterile injectable CDMO, for aseptic fill-finish, labeling, and packaging of mRNA respiratory vaccines to be produced in Canada. Similarly, in April 2023, Recipharm’s biologics division partnered with the Massachusetts Institute of Technology (MIT) to develop continuous manufacturing technology for mRNA therapeutics, aligning with the FDA’s initiative for a fully integrated, continuous production line for mRNA vaccines.
Given the increasing adoption of mRNA vaccines, rising research funding, and a strong pipeline of mRNA therapeutics, the mRNA therapeutics CDMO market is poised for significant growth in the coming years.
MRNA Therapeutics Contract Development And Manufacturing Organization Industry Overview
The market for mRNA contract development and manufacturing organizations is semi-consolidated. The players are engaged in various strategic activities like expansion of services, collaborations, partnerships, mergers, and acquisitions. Some of the key players in the mRNA CDMO market are Catalent Inc., Eurofins Scientific, Wuxi Biologics, Thermo Fisher Scientific Inc., Recipharm AB, and other companies.
MRNA Therapeutics Contract Development And Manufacturing Organization Market Leaders
-
Catalent, Inc.
-
Eurofins Scientific
-
Wuxi Biologics
-
Thermo Fisher Scientific Inc.
-
Recipharm Ab
*Disclaimer: Major Players sorted in no particular order
MRNA Therapeutics Contract Development And Manufacturing Organization Market News
- February 2024: Lonza, a global development and manufacturing partner collaborated with Oxford Nanopore Technologies. The partnership aims to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA (mRNA).
- September 2023: PackGene Biotech and Kudo Biotechnology partnered to provide high-quality, customized messenger RNA (mRNA) manufacturing services for drug and vaccine development.
MRNA Therapeutics Contract Development And Manufacturing Organization Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definitions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Adoption of mRNA Vaccines and Therapeutics
4.2.2 Increasing Research and Funding for mRNA Therapeutic Products
4.3 Market Restraints
4.3.1 Regulatory Challenges
4.3.2 Compliance Issues While Outsourcing
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD)
5.1 By Application
5.1.1 Viral Vaccines
5.1.2 Protein Replacement Therapies
5.1.3 Cancer Immunotherapies
5.1.4 Regenerative Medicine Therapy
5.2 By Indication
5.2.1 Cancer
5.2.2 Infectious Diseases
5.2.3 Metabolic and Genetic Diseases
5.2.4 Cardiovascular and Cerebrovascular Diseases
5.3 By End User
5.3.1 Biotechnology Companies
5.3.2 Pharmaceutical Companies
5.3.3 Government and Academic Research Institutes
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 United Kingdom
5.4.2.2 Germany
5.4.2.3 France
5.4.2.4 Spain
5.4.2.5 Italy
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 India
5.4.3.2 Japan
5.4.3.3 China
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of the Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific Inc.
6.1.2 Eurofins Scientific
6.1.3 Wuxi Biologics
6.1.4 Samsung Biologics
6.1.5 Catalent Inc.
6.1.6 Rentschler Biopharma SE
6.1.7 AGC Biologics
6.1.8 Recipharm AB (Publ)
6.1.9 Siegfried Holding AG
6.1.10 Boehringer Ingelheim
6.1.11 Fujifilm Diosynth Biotechnologies
6.1.12 Lonza
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
MRNA Therapeutics Contract Development And Manufacturing Organization Industry Segmentation
As per the scope of the report, the mRNA therapeutics class of drugs utilizes messenger RNA (mRNA) molecules to instruct cells in the body to produce specific proteins, which can have therapeutic effects. These therapeutics have shown promise in treating various diseases, including infectious diseases, cancer, and genetic disorders. The mRNA therapeutic CDMO market specifically focuses on the subset of CDMOs that specialize in mRNA-based therapeutics.
The mRNA therapeutics contract development and manufacturing organization market is segmented by application, indication, end user, and geography. By application, the market is segmented as viral vaccines, protein replacement therapies, cancer immunotherapies, and regenerative medicine therapy. By indication, the market is segmented infectious diseases, metabolic and genetic diseases, and cardiovascular and cerebrovascular diseases. By end user, the market is segmented as biotechnology companies, pharmaceutical companies, government and academic research institutes. By geography, the market is segmented North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions across the world. The report offers the value (in USD) for the above segments.
| By Application | |
| Viral Vaccines | |
| Protein Replacement Therapies | |
| Cancer Immunotherapies | |
| Regenerative Medicine Therapy |
| By Indication | |
| Cancer | |
| Infectious Diseases | |
| Metabolic and Genetic Diseases | |
| Cardiovascular and Cerebrovascular Diseases |
| By End User | |
| Biotechnology Companies | |
| Pharmaceutical Companies | |
| Government and Academic Research Institutes |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
MRNA Therapeutics Contract Development And Manufacturing Organization Market Research FAQs
How big is the MRNA Therapeutics Contract Development And Manufacturing Organization Market?
The MRNA Therapeutics Contract Development And Manufacturing Organization Market size is expected to reach USD 10.30 billion in 2024 and grow at a CAGR of 12.49% to reach USD 18.60 billion by 2029.
What is the current MRNA Therapeutics Contract Development And Manufacturing Organization Market size?
In 2024, the MRNA Therapeutics Contract Development And Manufacturing Organization Market size is expected to reach USD 10.30 billion.
Who are the key players in MRNA Therapeutics Contract Development And Manufacturing Organization Market?
Catalent, Inc., Eurofins Scientific, Wuxi Biologics, Thermo Fisher Scientific Inc. and Recipharm Ab are the major companies operating in the MRNA Therapeutics Contract Development And Manufacturing Organization Market.
Which is the fastest growing region in MRNA Therapeutics Contract Development And Manufacturing Organization Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in MRNA Therapeutics Contract Development And Manufacturing Organization Market?
In 2024, the Asia Pacific accounts for the largest market share in MRNA Therapeutics Contract Development And Manufacturing Organization Market.
What years does this MRNA Therapeutics Contract Development And Manufacturing Organization Market cover, and what was the market size in 2023?
In 2023, the MRNA Therapeutics Contract Development And Manufacturing Organization Market size was estimated at USD 9.01 billion. The report covers the MRNA Therapeutics Contract Development And Manufacturing Organization Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the MRNA Therapeutics Contract Development And Manufacturing Organization Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
MRNA Therapeutics Contract Development And Manufacturing Organization Industry Report
Statistics for the 2024 MRNA Therapeutics Contract Development And Manufacturing Organization market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. MRNA Therapeutics Contract Development And Manufacturing Organization analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
